登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002385 证券简称：大北农 公告编号：2026-012 北京大北农科技集团股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1.本次股东会未出现否决提案的情形； ①通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时间为：2026年2月9日9:15 一9:25，9:30一11:30和13:00一15:00； ②通过互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间为：2026年2月9日上午09:15至下午 15:00期间的任意时间。 2.现场会议召开地点：北京市海淀区澄湾街19号院大北农凤凰国际创新园行政楼104会议室 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间 (1)现场会议召开时间：2026年2月9日（星期一）下午14：30开始 (2)网络投票起止时间： 3.会议召开方式：采取现场投票与网络投票相结合的方式 4.会议召集 ...

Group 1 - The core point of the announcement is the resolution of the first extraordinary general meeting of shareholders held by Luyin Investment Group Co., Ltd. on February 9, 2026, with no rejected proposals [1][2] - The meeting was held at the specified location in Jinan, and was presided over by the chairman, Yang Yaodong, in compliance with the Company Law and the company's articles of association [2][3] - All nine current directors and the acting secretary of the board attended the meeting, ensuring proper representation [2] Group 2 - One of the key resolutions passed was regarding the execution of related party transactions for the year 2025 and the expected related party transactions for 2026, which was approved by the shareholders [3] - Related shareholders, Shandong Development Investment Holding Group Co., Ltd. and Shandong Guohui Fund Management Co., Ltd., abstained from voting on the proposal due to legal requirements [3] - The legal opinion provided by Shandong Qilu Law Firm confirmed that the meeting's procedures and resolutions were in accordance with legal and regulatory requirements, validating the decisions made [5]

Core Viewpoint - Tongwei Co., Ltd. announces the interest payment details for its convertible bonds "Tong 22 Convertible Bonds" which will begin on February 24, 2026, covering the interest period from February 24, 2025, to February 23, 2026 [2][4] Group 1: Convertible Bond Issuance Overview - The company issued 120 million convertible bonds on February 24, 2022, with a total value of 1.2 billion yuan, each with a face value of 100 yuan [2][3] - The bonds have a six-year term, maturing on February 23, 2028, with a tiered interest rate structure: 0.20% for the first year, 0.40% for the second year, 0.60% for the third year, 1.50% for the fourth year, 1.80% for the fifth year, and 2.00% for the sixth year [2][3] Group 2: Interest Payment Details - The interest payment method is annual, with the first payment scheduled for February 24, 2026, at a rate of 1.50% (including tax), resulting in an interest payment of 1.50 yuan per bond [8][11] - The interest payment record date is February 13, 2026, and the ex-dividend date is February 24, 2026 [9] Group 3: Tax Implications - Individual investors are subject to a 20% tax on interest income, resulting in a net payment of 1.20 yuan per bond after tax [11] - Resident enterprises are responsible for their own tax payments on bond interest, with the gross amount remaining at 1.50 yuan per bond [12] - Non-resident enterprises will be exempt from corporate income tax on bond interest from January 1, 2026, to December 31, 2027, maintaining the gross amount at 1.50 yuan per bond [13]

证券代码：600996 证券简称：贵广网络 公告编号：2026-005 贵州省广播电视信息网络股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ■ 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年2月9日 (二)股东会召开的地点：贵州省贵阳市观山湖区金阳南路36号贵广网络大楼4-1会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，由董事长代青松先生主持。会议采用现场投票和网络投票相结合的表决 方式。本次会议的召集、召开符合《公司法》《公司章程》有关规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席9人； 2、公司董事会秘书黄宗文先生出席会议；公司其他高管列席会议。 二、议案审议情况 (一)累积投票议案表决情况 1、关于公司董事会非独立董事换届选举的议案 ■ 2、关于公司董事会 ...

Core Viewpoint - Xiamen Tungsten Co., Ltd. intends to acquire a 39% stake in Jiujiang Dadi Mining Development Co., Ltd. to secure upstream tungsten raw material supply and increase self-sufficiency in tungsten resources [2][4][18] Transaction Overview - The company signed a Letter of Intent for the transfer of shares with Beijing Shangdaxin Investment Co., Ltd., agreeing to pay an intention fee of 28 million yuan [2][4] - The acquisition is still in the planning stage, and the final transaction details, including the specific acquisition ratio and price, will depend on due diligence and negotiations [3][4] - The transaction is expected not to constitute a major asset restructuring as defined by relevant regulations [4][5] Counterparty Information - The transferor, Beijing Shangdaxin Investment Co., Ltd., is a limited liability company with a registered capital of 30 million yuan and is not related to the company [7] Target Company Information - Jiujiang Dadi Mining Development Co., Ltd. is a limited liability company with a registered capital of 120 million yuan, currently in the exploration stage with no operational revenue [8][9] - The company holds mining rights for the Yangshidian copper-molybdenum polymetallic mine and has a subsidiary, Xiushui Kunshan Tungsten Mine Co., Ltd. [9][10] Purpose and Impact of Acquisition - The acquisition aims to enhance the company's mineral resource reserves, improve raw material self-sufficiency, reduce procurement risks, and support stable production operations [18]

Meeting Overview - The first extraordinary general meeting of shareholders for 2026 was held on February 9, 2026, at 15:00, with both on-site and online voting options available [5][7] - The meeting was convened by the company's board of directors and presided over by Chairman Zeng Shengqiang [8][9] Attendance - A total of 1,289 shareholders and their representatives attended the meeting, representing 175,159,746 shares, which is 28.7070% of the total voting shares [9][10] - Among the attendees, 1,287 were small investors, representing 70,387,975 shares, or 11.5359% of the total voting shares [10][12] Voting Results - The following proposals were approved during the meeting: 1. Proposal to provide guarantees for the subsidiary's credit limit application was approved with 173,242,186 votes in favor, accounting for 98.9053% of the valid votes [13] 2. Proposal for the wholly-owned subsidiary to initiate public REITs application and issuance was approved with 173,644,386 votes in favor, representing 99.1349% of the valid votes [14] 3. Proposal to authorize management to handle the public REITs application and issuance was approved with 173,657,686 votes in favor, which is 99.1425% of the valid votes [15] Legal Opinion - The meeting was witnessed by lawyers from Zhejiang Tian Ce (Shenzhen) Law Firm, who confirmed that the meeting's procedures and voting results were in compliance with legal and regulatory requirements [17]

Core Viewpoint - North China Pharmaceutical Co., Ltd. has announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Cefprozil Tablets (0.25g) from the National Medical Products Administration, which is expected to enhance the company's product portfolio and market competitiveness [1][6]. Group 1: Drug Registration Details - The Drug Registration Certificate for Cefprozil Tablets (0.25g) was approved by the National Medical Products Administration [1]. - Cefprozil is a second-generation cephalosporin antibiotic, initially developed by Bristol-Myers Squibb in 1991, and was the first oral cephalosporin approved by the FDA for treating pediatric otitis media and sinusitis [1][2]. Group 2: Indications and Market Situation - The approved indications for Cefprozil in China include treatment for upper respiratory infections, lower respiratory infections, and skin and soft tissue infections caused by sensitive bacteria [2]. - Currently, there are 10 companies, including Huamin, that hold the Drug Registration Certificate for Cefprozil Tablets (0.25g) in China. Sales figures for Cefprozil Tablets in sample hospitals from 2023 to the first three quarters of 2025 are reported as 141.7 million, 134.99 million, and 74.22 million yuan respectively [5]. Group 3: Research and Development Investment - The cumulative R&D investment for the drug has reached 14.6458 million yuan (unaudited) [3]. Group 4: Future Prospects - Following the receipt of the Drug Registration Certificate, the company can arrange for production and market the product [4].

证券代码：600056 证券简称：中国医药 公告编号：临2026-015号 （四）本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为有效决议。 二、会议审议情况 本次会议审议并通过如下议案： 中国医药健康产业股份有限公司 第十届董事会第1次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 （一）中国医药健康产业股份有限公司(以下简称"公司")第十届董事会第1次会议（以下简称"本次会 议"）于2026年2月9日以现场结合通讯方式召开，全体董事共同推举董事杨光先生主持本次会议，公司 相关高级管理人员列席了本次会议。 （二）本次会议通知于2026年2月4日以邮件、短信、电话或传真的方式向全体董事发出。 （三）本次会议应参加会议董事8名，实际参加会议董事8名。 （一）审议通过了《关于选举董事长的议案》。 经决议，董事会选举杨光先生担任公司董事长职务，并为代表公司执行公司事务的董事担任公司法定代 表人，任期自本次董事会审议通过之日至第十届董事会届满。 表决结果：同意8票；反对0票；弃权0票。 ...

Meeting Overview - The first extraordinary general meeting of shareholders for 2026 was convened by the board of directors [1] - The meeting was held both in-person and via online voting [2] Meeting Details - The in-person meeting took place on February 9, 2026, at 15:00 [3] - Online voting was available from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 on the same day [3] - The venue for the in-person meeting was located at East China Software Co., Ltd., Beijing [4] Attendance - A total of 7 shareholders attended the meeting in person, representing 1,111,120,869 shares, which is 34.6631% of the total voting shares [6] - Additionally, 1,382 shareholders participated via online voting, representing 75,018,673 shares, or 2.3403% of the total voting shares [6] - In total, 1,389 shareholders participated, representing 1,186,139,542 shares, or 37.0035% of the total voting shares [6] Resolutions Passed - The meeting approved the election of the non-independent directors for the ninth board, including Mr. Xue Xiangdong, Mr. Hou Zhiguo, Ms. Ye Li, Mr. Ma Botao, and Ms. Zhang Wen, for a term of three years [8] - The voting results for the election of Mr. Xue Xiangdong showed 1,174,322,419 shares in favor, accounting for 99.0037% of the valid votes [8] - The election of independent directors, including Mr. Pan Changyong, Mr. Lin Zhong, and Ms. Shen Chang'e, was also approved, with similar high approval rates [12][14] - The meeting approved the appointment of members for the audit committee, including Ms. Shen Chang'e, Mr. Pan Changyong, and Mr. Ma Botao, with approval rates exceeding 99% [15][17] - Amendments to the company's articles of association and governance systems were also passed, with significant majority support [19][20] Legal Compliance - The meeting's procedures were confirmed to comply with relevant laws and regulations, ensuring the legitimacy of the meeting and the validity of the voting results [21]

Group 1 - The company received a resignation report from non-independent director Mr. Ao Hui on February 8, 2026, due to adjustments in the corporate governance structure [1] - Mr. Ao Hui's resignation will not lead to the board of directors falling below the legal minimum number, and it will not affect the normal operation of the board or the company's daily management and production [1] - The company held a staff representative meeting on February 9, 2026, to elect Mr. Ao Hui as the employee director of the ninth board of directors, which will serve until the term of the ninth board expires [1] Group 2 - After being elected as the employee director, the number of directors who also hold senior management positions and those who are employee representatives does not exceed half of the total number of directors, complying with relevant laws and regulations [2] - Mr. Ao Hui has a diverse background, having held various positions in the Chongqing region, including roles in economic management and state-owned asset management, and currently serves as the deputy secretary of the party committee and chairman of the labor union at the company [3]